Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ)
CNY 8.32
(-6.41%)
CNY 8.32
(-6.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -115.87 Million CNY | 9.55% |
| 2022 | -128.11 Million CNY | 57.45% |
| 2021 | -301.09 Million CNY | 7.36% |
| 2020 | -325.01 Million CNY | 26.51% |
| 2019 | -442.26 Million CNY | -133.58% |
| 2018 | -189.34 Million CNY | -90.31% |
| 2017 | -99.49 Million CNY | -43.73% |
| 2016 | -69.22 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -85.01 Million CNY | 26.63% |
| 2024 Q2 | 21.32 Million CNY | 125.08% |
| 2023 Q4 | -115.87 Million CNY | 55.07% |
| 2023 Q1 | -97.73 Million CNY | 23.71% |
| 2023 Q2 | -92.18 Million CNY | 5.68% |
| 2023 Q3 | -257.91 Million CNY | -179.79% |
| 2023 FY | -115.87 Million CNY | 9.55% |
| 2022 Q1 | -268.68 Million CNY | 10.76% |
| 2022 FY | -128.11 Million CNY | 57.45% |
| 2022 Q4 | -128.11 Million CNY | -11.11% |
| 2022 Q3 | -115.29 Million CNY | 30.27% |
| 2022 Q2 | -165.35 Million CNY | 38.46% |
| 2021 FY | -301.09 Million CNY | 7.36% |
| 2021 Q4 | -301.09 Million CNY | -45.77% |
| 2021 Q3 | -206.55 Million CNY | 40.54% |
| 2021 Q2 | -347.38 Million CNY | 18.78% |
| 2021 Q1 | -427.69 Million CNY | -31.59% |
| 2020 FY | -325.01 Million CNY | 26.51% |
| 2020 Q1 | 442.26 Million CNY | 200.0% |
| 2020 Q4 | -325.01 Million CNY | -291.7% |
| 2020 Q2 | -382.84 Million CNY | -186.56% |
| 2020 Q3 | -82.97 Million CNY | 78.33% |
| 2019 FY | -442.26 Million CNY | -133.58% |
| 2019 Q4 | -442.26 Million CNY | 0.0% |
| 2019 Q1 | -310.96 Million CNY | 0.0% |
| 2018 FY | -189.34 Million CNY | -90.31% |
| 2017 FY | -99.49 Million CNY | -43.73% |
| 2016 FY | -69.22 Million CNY | 0.0% |